glp-1 receptor agonist use and risk of suicide death agonists or suicide attempts – A nationwide cohort and self-controlled case series study Frontiers | Glucagon-like peptide-1 receptor

Specifically, we examined the association between engagement status (engaged vs nonngaged) and weight loss at each month (months 1 to 5) using ordinary least squares regression, controlling for potential confounders We regressed percentage weight change (%) from baseline on engagement status (engaged vs nonengaged), adjusting for clinical indicators such as age, gender, baseline weight, BMI category, presence of T2D, presence of high cholesterol, and presence of high blood pressure

These positive results prompted the first clinical trial of exenatide in treating patients with IIH

The rate of adverse events, particularly gastrointestinal side effects, is not much different from what you see with other GLP-1 drugs, he says

The magnitude and the long-term clinical impact of these effects is still being evaluated, but the data available suggest GLP-1 RAs (and likely SGLT2 inhibitors) play a main role in the treatment of NAFLD

Surg Innov 24(6):616624

Figure 1 Statements Author contributions RC: Writing review & editing, Writing original draft